BioPharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The October 2012 issue of BioPharma Dealmakers showcases companies with partnering opportunities and contains a focus feature on those active in Neuro-partnering. This week, find out about how you can collaborate with Roche Partnering.
New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management.
Click here for more information on Alzheimer's partnering opportunities.
SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing.
A current affair in MS Tracey Baas doi:10.1038/scibx.2012.1223 A European team has used the diabetes drug glibenclamide to block inflammation-induced neurodegeneration in mice. The team plans to test the nonspecific inhibitor of the cationic channel TRPM4 in an investigator-led clinical trial in multiple sclerosis and is looking for pharma partners to develop more specific antagonists of the target. Full Text | PDF
Genomics in the Big Apple Tim Fulmer doi:10.1038/scibx.2012.1224 The New York Genome Center launched its translational research unit last week with the appointment of Robert Darnell as president and scientific director. Darnell will oversee the development of internal research projects as well as the hiring of researchers to fill out the unit. Full Text | PDF
Thinking outside the amyloid box Lev Osherovich doi:10.1038/scibx.2012.1225 Therapeutic strategies for Alzheimer's disease that aim to reduce levels of β-amyloid have thus far come up empty-handed in the clinic. Now, two European teams have proposed contrasting strategies focused on hitting intermediate protein fragments and enzymatic steps in the pathway that produces amyloid. Full Text | PDF
Micromanaging tolerance Kai-Jye Lou doi:10.1038/scibx.2012.1226 Researchers at Northwestern University and the Myelin Repair Foundation have simplified an autologous cell-based strategy for promoting antigen-specific tolerance by replacing splenic leukocytes with synthetic microparticles as the antigen carrier. The groups are planning to first develop the therapy and establish proof of concept in autoimmune indications for which the key antigen is known before moving forward in MS. Full Text | PDF
Prostate-specific membrane antigen (PSMA; FOLH1; GCPII) doi:10.1038/scibx.2012.1227 Human and mouse studies suggest inhibiting GCPII could help treat cognitive impairments associated with MS. Full Text | PDF
Transient receptor potential cation channel subfamily M member 4 (TRPM4) doi:10.1038/scibx.2012.1228 Patient sample and mouse studies suggest inhibiting TRPM4 could help treat MS. Full Text | PDF
Not applicable doi:10.1038/scibx.2012.1229 An in vitro study identified a small molecule inhibitor of breast cancer stem cell growth that could help treat the disease. Full Text | PDF
Glycogen liver phosphorylase (PYGL) doi:10.1038/scibx.2012.1230 A study in mice suggests inhibiting PYGL could help treat hypoxic tumors. Full Text | PDF
Histone deacetylase 8 (HDAC8) doi:10.1038/scibx.2012.1231 In vitro studies identified an HDAC8-selective inhibitor that could help treat cancer. Full Text | PDF
Protein kinase B (PKB; PKBA; AKT; AKT1) doi:10.1038/scibx.2012.1232 In vitro studies suggest identifying the type of AKT1 mutations in patients with cancer could help guide treatment decisions. Full Text | PDF
Transforming growth factor-β receptor II (TGFβ-RII; TGFBR2); mediator complex subunit 12 (MED12) doi:10.1038/scibx.2012.1233 In vitro studies suggest inhibiting TGFBR2 could help prevent resistance to targeted therapies in lung cancer. Full Text | PDF
Angiopoietin-like 8 (ANGPTL8); ANGPTL3 doi:10.1038/scibx.2012.1234 In vitro and mouse studies suggest inhibiting activation of ANGPTL8 or ANGPTL3 could help treat hyperlipidemia. Full Text | PDF
Calcineurin doi:10.1038/scibx.2012.1235 In vitro and mouse studies suggest inhibiting calcineurin could help treat biliary pancreatitis. Full Text | PDF
Dipeptidyl peptidase-4 (DPP-4) doi:10.1038/scibx.2012.1236 Mouse studies suggest blocking DPP-4 could help prevent neutropenia during chemotherapy or radiation therapy. Full Text | PDF
Not applicable doi:10.1038/scibx.2012.1237 Mouse studies suggest a mutant form of SARS-associated coronavirus could be used to vaccinate against the infection. Full Text | PDF
Tumor necrosis factor-α–induced protein 6 (TNFAIP6; TSG6) doi:10.1038/scibx.2012.1238 Mouse studies suggest TSG6 inhibition could help treat asthma. Full Text | PDF
Eukaryotic translation initiation factor 4E (eIF4E); eIF4E binding protein 2 (eIF4EBP2) doi:10.1038/scibx.2012.1239 Mouse studies suggest inhibition of eIF4E signaling could help treat autism spectrum disorder (ASD). Full Text | PDF
Tissue inhibitor of metalloproteinases 3 (TIMP3) doi:10.1038/scibx.2012.1240 Mouse studies suggest TIMP3 could help treat traumatic brain injury (TBI). Full Text | PDF
Opiate receptor-like 1 (OPRL1) doi:10.1038/scibx.2012.1241 Rat and primate studies suggest OPRL1 agonists could help treat dyskinesias induced by the PD drug L-dopa. Full Text | PDF
Profiling tumor-derived microvesicles in the blood of patients with glioblastoma multiforme (GBM) doi:10.1038/scibx.2012.1242 A microfluidic system for profiling tumor-derived microvesicles in the blood of patients with GBM could help guide treatment decisions. Full Text | PDF
Mouse model for Parkinson's disease (PD) doi:10.1038/scibx.2012.1243 Nontransgenic mice receiving α-synuclein (SNCA) could be useful for studying pathogenesis of PD and evaluating therapeutic candidates. Full Text | PDF
Engineered HPV particles that encapsulate viral genes for intravaginal vaccination against infection doi:10.1038/scibx.2012.1244 Mouse studies suggest intravaginal immunization using engineered HPV particles could help protect against mucosal pathogens. Full Text | PDF
Optogenetic gene therapy to treat focal neocortical epilepsy doi:10.1038/scibx.2012.1245 Rat studies suggest optogenetic gene therapy could help treat focal neocortical epilepsy. Full Text | PDF
Peptide-linked microparticles for inducing immune tolerance doi:10.1038/scibx.2012.1246 Mouse studies suggest peptide-linked microparticles that induce immune tolerance could be useful for treating immune-mediated diseases such as multiple sclerosis (MS). Full Text | PDF
Imaging immune disease using multicolor light sheet fluorescent microscopy (LSFM) doi:10.1038/scibx.2012.1247 High-resolution LSFM could help characterize the immune response in preclinical disease models. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment